Antimitotic sulfonamides inhibit microtubule assembly dynamics and cancer cell proliferation

Biochemistry

Volumn 45, Issue 17, 2006, Pages 5440-5449

  Mohan, Renu ^a   Banerjee, Mithu ^b   Ray, Anasuya ^c   Manna, Tapas ^c   Wilson, Leslie ^c   Owa, Takashi ^d   Bhattacharyya, Bhabatarak ^b   Panda, Dulal ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY BOMBAY   (India)

^b BOSE INSTITUTE   (India)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; ENZYME INHIBITION; SELF ASSEMBLY; TUMORS;

CANCER CELLS; MICROTUBULES; MITOSIS; PHOSPHORYLATION;

AMINES;

ANTIMITOTIC AGENT; ER 67836; ER 67880; ER 68378; ER 68384; ER 68394; INDOLE DERIVATIVE; MICROTUBULE PROTEIN; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; PROTEIN BCL 2; SULFONAMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE; CELL KILLING; CELL PROLIFERATION; CHROMOSOME; CONTROLLED STUDY; DEPOLYMERIZATION; DRUG EFFECT; DRUG MECHANISM; HELA CELL; HUMAN; HUMAN CELL; IC 50; INTERPHASE; MICROTUBULE ASSEMBLY; MITOSIS INHIBITION; MITOSIS SPINDLE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN POLYMERIZATION;

AMINOPHENOLS; ANTIMITOTIC AGENTS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL PROLIFERATION; HELA CELLS; HUMANS; INDOLES; INTERPHASE; MICROTUBULES; MITOSIS; MITOTIC SPINDLE APPARATUS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES;

EID: 33646348698     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi0523409     Document Type: Article

References (55)

1. Maren, T. H., and Conroy, C. W. (1993) A new class of carbonic anhydrase inhibitor, J Biol. Chem. 268, 26233-26239.
2. Scozzafava, A., Owa, T., Mastrolorenzo, A., and Supuran, C. T. (2003) Anticancer and antiviral sulfonamides, Curr. Med. Chem. 10, 925-953.
3. Owa, T., Yoshino, H., Okauchi, T., Yoshimatsu, K., Ozawa, Y., Sugi, N. H., Nagasu, T., Koyanagi, N., and Kitoh, K. (1999) Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle, J. Med. Chem. 42, 3789-3799.
4. Koyanagi, N., Nagasu, T., Fujita, F., Watanabe, T., Tsukahara, K., Funahashi, Y., Fujita, M., Taguchi, T., Yoshino, H., and Kitoh, K. (1994) In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors, Cancer Res. 54, 1702-1706.
5. Ghosh, K. A., Swanson, M. L., Cho, H., Leschenko, S., Hussain, A. K., Kays, S., Walker, E. D., Koh, Y., and Mitsuya, H. (2005) Structure-based design: Synthesis and biological evaluation of a series of novel cyclo-amide derived HIV-1 protease inhibitors, J. Med. Chem. 48, 3576-3585.
6. Yeung, M. C., Klein, L. L., Flentge, A. C., Randolph, T. J., Zhao, C., Ming, H. S., Tatyana, D., Vincent, S. S., and Kempf, J. D. (2005) Oximinosulfonamides as potent HIV protease inhibitors, Bioorg. Med. Chem. Lett. 15, 2275-2278.
7. Fung, B. H., Kisrchenbaum, L. H., and Hameed, R. (2000) Amprenavir: A new human immunodeficiency virus type1 protease inhibitor, Clin. Ther. 22, 549-572.
8. Yokoi, A., Kuromitsu, J., Kawai, T., Nagasu, T., Sugi, N. H., Yoshimatsu, K., Yoshino, H., and Owa, T. (2002) Profiling novel sulfonamide antitumor agents with cell-based phenotypic screens and array-based gene expression analysis, Mol. Cancer Ther. 1, 275-286.
9. Oda, Y., Owa, T., Sato, T., Boucher, B., Daniels, S., Yamanaka, H., Shinohara, Y., Yokoi, A., Kuromitsu, J., and Nagasu, T. (2003) Quantitative chemical proteomics for identifying candidate drug targets, Anal. Chem. 75, 2159-2165.
10. Owa, T., Yokoi, A., Yamazaki, K., Yoshimatsu, K., Yamori, T., and Nagasu, T. (2002) Array-based structure and gene expression relationship study of antitumor sulfonamides including [2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4- methoxybenzenesulfonamide and N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide, J. Med. Chem. 45, 4913-4922.
11. Owa, T., Okauchi, T., Yoshimatsu, K., Sugi, N. H., Ozawa, Y., Nagasu, T., Koyanagi, N., Okabe, T., Kitoh, K., and Yoshino, H. (2000) A focused compound library of novel N-(7-indolyl)-benzenesulfonamides for the discovery of potent cell cycle inhibitors, Bioorg. Med. Chem. Lett. 10, 1223-1226.
12. Ozawa, Y., Sugi, N. H., Nagasu, T., Owa, T., Watanabe, T., Koyanagi, N., Yoshino, H., Kitoh, K., and Yoshimatsu, K. (2001) E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo, Eur. J. Cancer. 37, 2275-2282.
13. Owa, T., Yoshino, H., Yoshimatsu, K., and Nagasu, T. (2001) Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents, Curr. Med. Chem. 8, 1487-1503.
14. Fukuoka, K., Usuda, J., Iwamoto, Y., Fukumoto, H., Nakamura, T., Yoneda, T., Narita, N., Saijo, N., and Nishio, K. (2001) Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells, Invest. New Drugs 19, 219-227.
15. Laconde, G., Pommery, N., Depreux, P., Berthelot, P., and Henichart, J. P. (2003) New analogues of the anticancer E7070: synthesis and pharmacology, J. Enzyme Inhib. Med. Chem. 18, 89-94.
16. Yoshimatsu, K., Yamaguchi, A., Yoshino, H., Koyanagi, N., and Kitoh, K. (1997) Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin, Cancer Res. 57, 3208-3213.
17. Gwaltney, S. L., II, Imade, H. M., Li, Q., Gehrke, L., Credo, R. B., Warner, R. B., Lee, J. Y., Kovar, P., Frost, D., Ng, S. C., and Sham, H. L. (2001) Novel sulfonate derivatives: potent antimitotic agents, Bioorg. Med. Chem. Lett. 11, 1671-1673.
18. Iwamoto, Y., Nishio, K., Fukumoto, H., Yoshimatsu, K., Yamakido, M., and Saijo, N. (1998) Preferential binding of E7010 to murine beta 3-tubulin and decreased beta 3-tubulin in E7010-resistant cell lines, Jpn. J. Cancer Res. 89, 954-962.
19. Nihei, Y., Suzuki, M., Okano, A., Tsuji, T., Akiyama, Y., Tsuruo, T., Saito, S., Hori, K., and Sato, Y. (1999) Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy, Jpn. J. Cancer Res. 90, 1387-1395.
20. Van Kesteren, C., Beijnen, J. H., and Schellens, J. H. (2002) E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer, Anti-Cancer Drugs 13, 989-997.
21. Funahashi, Y., Koyanagi, N., and Kitoh, K. (2001) Effect of E7010 on liver metastasis and life span of syngeneic C57BL/6 mice bearing orthotopically transplanted murine Colon 38 tumor, Cancer Chemother. Pharmacol. 47, 179-184.
22. Yamamoto, K., Noda, K., Yoshimura, A., Fukuoka, M., Furuse, K., and Niitani, H. (1998) Phase I study of E7010, Cancer Chemother. Pharmacol. 42, 127-134.
23. Smyth, J. F., Aamdal, S., Awada, A., Dittrich, C., Caponigro, F., Schoffski, P., Gore, M., Lesimple, T., Djurasinovic, N., Baron, B., Ravic, M., Fumoleau, P., and Punt, C. J. (2005) EORTC new drug development and melanoma groups. Phase II study of E7070 in patients with metastatic melanoma, Ann. Oncol. 16, 158-161.
24. Supuran, C. T. (2003) Indisulam: an anticancer sulfonamide in clinical development, Expert Opin. Invest. Drugs 12, 283-287.
25. Banerjee, M., Poddar, A., Mitra, A., Surolia, A., Owa, T., and Bhattacharya, B. (2005) Sulfonamide drugs binding to the colchicine site of tubulin: Thermodynamic analysis of the drug-tubulin interactions by isothermal titration calorimetry, J. Med. Chem. 48, 547-555.
26. Nguyen, T. L., McGrath, C., Hermone, A. R., Burnett, J. C., Zaharevitz, D. W., Day, B. W., Wipf, P., Hamel, E., and Gussio, R. (2005) A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach, J. Med. Chem. 48, 6107-6116.
27. Jordan, M. A., and Wilson, L. (2004) Microtubules as a target for anticancer drugs, Nat. Rev. 4, 253-265.
28. Lodish, H., Baltimore, D., Berk, A., Zipursky, S. L., Matsudaira, P., and Darnell, J. (1999) Molecular Cell Biology, W. H. Freeman, New York.
29. Nogales, E., Whittaker, M., Milligan, R. A., and Downing, K. H. (1999) High resolution model of the microtubule, Cell 96, 76-78.
30. Desai, A., and Mitchison, T. J. (1997) Microtubule polymerization dynamics, Annu. Rev. Cell Biol. 13, 83-117.
31. Wilson, L., Panda, D., and Jordan, M. A. (1999) Modulation of microtubule dynamics by drugs: A paradigm for the action of cellular regulators, Cell Struct. Fund. 24, 329-335.
32. Panda, D., Miller, H. P., Islam, K., and Wilson, L. (1997) Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action, Proc. Natl. Acad. Sci. U.S.A. 94, 10560-10564.
33. Hamel, E. (1996) Antimitotic natural products and their interactions with tubulin, Med. Res. Rev. 16, 207-231.
34. Panda, D., DeLuca, K., Williams, D., Jordan, M. A., and Wilson, L. (1998) Antiproliferative mechanism of action of cryptophycin-52: Kinetic stabilization of microtubule dynamics by high affinity binding to microtubule ends, Proc. Natl. Acad. Sci. U.S.A. 95, 9313-9318.
35. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesh, H., Kenney, S., and Boyd, M. R. (1990) New colorimetric cytotoxicity assay for anticancer drug screening, J. Natl. Cancer Inst. 82, 1107-1112.
36. Gupta, K., Bishop, J., Peck, A., Brown, J., Wilson, L., and Panda, D. (2004) Antimitotic antifungal compound benomyl inhibits brain microtubule polymerization and dynamics and cancer cell proliferation at mitosis, by binding to a novel site in tubulin, Biochemistry 43, 6645-6655.
37. Panda, D., Rathinasamy, K., Santra, M. K., and Wilson, L. (2005) Kinetic suppression of microtubule dynamic instability by griseofulvin: Implications for its possible use in the treatment of cancer, Proc. Natl. Acad. Sci. U.S.A. 102, 9878-9883.
38. Wang, L. G., Lui, X. M., Kruis, W., and Budman, D. R. (1999) The effect of antimicrotubule agents on the signal transduction pathways of apoptosis: A review, Cancer Chemother. Pharmacol. 44, 355-361.
39. Negri, L., Donzelli, M., Bernardi, R., Rossi, L., Burkle, A., and Scovassi, I. (1997) Multiparametric staining to identify apoptotic human cells, Exp. Cell Res. 234, 174-177.
40. Blagoskonny, M. V., Giannakakou, P., el-Deiry, W. S., Kingston, D. G., Higgs, P. I., Neckers, L., and Fojo, T. (1997) Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death, Cancer Res. 57, 130-135.
41. Haldar, S., Jena, N., and Croce, C. M. (1995) Inactivation of bcl-2 by phosphorylation, Proc. Natl. Acad. Sci. U.S.A. 92, 4507-4511.
42. Khan, S. H., and Wahl, G. M. (1998) P53 and pRb prevent rereplication in response to microtubule inhibitors by mediating a reversible Gl arrest, Cancer Res. 58, 396-401.
43. Panda, D., Daijo, J. E., Jordan, M. A., and Wilson, L. (1995) Kinetic stabilization of microtubule dynamics at steady state in vitro by substoichiometric concentrations of tubulin-colchicine complex, Biochemistry 34, 9921-9929.
44. Jordan, M. A., Wendell, K., Gardiner, S., Derry, W. B., Copp, H., and Wilson, L. (1996) Mitotic block in HeLa cells by low concentrations of paclitaxel (taxol) results in abnormal mitotic exit and apoptotic cell death, Cancer Res. 56, 816-825.
45. Lin, H. L., Chang, Y. F., Lui, T. Y., Wu, C. W., and Chi, C. W. (1998) Submicromolar paclitaxel induces apoptosis in human gastric cancer cells at early G1 phase, Anticancer Res. 18, 3443-3449.
46. Abal, M., Andreu, J. M., and Barasoain, T. (2003) Taxanes: microtubule and centrosome targets and cell cycle dependent mechanisms of action, Curr. Cancer Drug Targets 3, 193-203.
47. Boise, L. H., Ganzalel-Garcia, M., Postema, C. E., Ding, L., Lindsten, T., Turka, L. A., Mao, X., Numez, G., and Thompson, C. B. (1993) Bcl-x1, a bcl-2 related gene that functions as a dominant regulator of apoptotic cell death, Cell 74, 597-608.
48. Haldar, S., Basu, A., and Croce, C. M. (1997) Bcl-2 is the guardian of microtubule integrity, Cancer Res. 57, 229-233.
49. Blagoskonny, M. V. (2001) Unwinding the loop of bcl-2 phosphorylation. Leukemia 15, 869-874.
50. Scatena, C. D., Stewart, Z. A., Mays, D., Tang, L. J., Keefer, C. J., Leach, S. D., and Pietenpol, J. A. (1998) Mitotic phosphorylation of bcl-2 during normal cell cycle progression and taxol-induced growth arrest, J. Biol. Chem. 273, 30777-30784.
51. Basu, A., and Haldar, S. (1998) Microtubule-damaging drugs triggered bcl2 phosphorylation- requirement of phosphorylation on both serine-70 and serine-87 residues of bcl2 protein, Int. J. Oncol. 13, 659-664.
52. Lanni, J. S., and Jacks, T. (1998) Characterization of the p53-dependent post mitotic checkpoint following spindle disruption, Mol. Cell. Biol. 18, 1055-1064.
53. Giannakakou, P., Nakauo, M., Nicolaou, K. C., O'Brate, A., Yu, J., Blagosklonny, M. V., Greber, U. F., and Fojo, T. (2002) Enhanced microtubule dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics, Proc. Natl. Acad. Sci. U.S.A. 99, 10855-10860.
54. Lanni, J. S., Lowe, S. W., Licitra, E. J., Liu, J. O., and Jacks, T. (1997) P53-independent apoptosis induced by paclitaxel through an indirect mechanism, Proc. Natl. Acad. Sci. U.S.A. 94, 9679-9683.
55. Woods, C. M., Zhu, J., McQueney, P. A., Bollag, D., and Lazarides, E. (1995) Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway, Mol. Med. (Tokyo, Jpn) 1, 506-526.